ZG 0895
Alternative Names: ZG-0895; ZG0895 hydrochloride; ZG0895.HClLatest Information Update: 16 Jul 2024
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 May 2024 Adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the trial at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 29 May 2023 Suzhou Zelgen Biopharmaceuticals plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in China (SC, Injection), in July 2023 , (NCT05877664)
- 14 Apr 2023 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)